Xenetic Biosciences’ (XBIO) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright restated their neutral rating on shares of Xenetic Biosciences (NASDAQ:XBIO) in a research report report published on Tuesday, Benzinga reports. HC Wainwright also issued estimates for Xenetic Biosciences’ Q3 2024 earnings at ($0.14) EPS, Q4 2024 earnings at ($0.20) EPS, FY2024 earnings at ($1.01) EPS and FY2025 earnings at ($0.66) EPS.

Xenetic Biosciences Stock Performance

XBIO stock opened at $4.33 on Tuesday. Xenetic Biosciences has a 52 week low of $2.78 and a 52 week high of $5.97. The company has a market capitalization of $6.67 million, a PE ratio of -1.48 and a beta of 2.29. The company’s 50-day simple moving average is $3.97 and its 200 day simple moving average is $3.98.

Xenetic Biosciences (NASDAQ:XBIO) last announced its earnings results on Tuesday, August 13th. The company reported ($0.83) EPS for the quarter, hitting the consensus estimate of ($0.83). Xenetic Biosciences had a negative net margin of 182.99% and a negative return on equity of 43.40%. The company had revenue of $0.73 million for the quarter, compared to analysts’ expectations of $0.54 million. On average, analysts forecast that Xenetic Biosciences will post -0.96 EPS for the current year.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.